Manage Adverse Events From Immunotherapy and Targeted Therapy for Melanoma

Elisa Becze, BA, ELS, Editor


New targeted and immunotherapy drug approvals have offered improved survival and disease outcomes for patients with melanoma, but the new therapies are also associated with a range of adverse events (AEs) that differ from those associated with chemotherapy. Oncology nurses will need to shift their thinking to best manage those AEs.

View Article @

ONS Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Articles